Context Therapeutics (CNTX) Insider Smith Buys 45,000 Shares

Karen Smith Adds to Context Therapeutics Stake

Context Therapeutics Inc. (NasdaqCM: CNTX) saw additional insider activity on June 24, 2026, when Karen Smith purchased 45,000 shares of the clinical-stage biopharmaceutical company. This transaction follows a series of similar purchases by other insiders on the exact same date as the stock trades in the sub-dollar range.

Stock Trades Near 50-Day Moving Average

Shares of Context Therapeutics changed hands at $0.58 on Saturday. The stock sits above its 50-day moving average of $0.49, though it remains far below its 200-day moving average of $1.60. Over the past fifty-two weeks, the biotechnology company has traded in a range from a low of $0.34 to a high of $3.62, giving the firm a market capitalization of $34.45 million.

Multiple Insiders Make Identical Purchases

Beyond Karen Smith's acquisition, several other individuals connected to Context Therapeutics picked up matching stakes on June 24, 2026. Insider Walker Luke Nathaniel acquired 45,000 shares, Linda West purchased 45,000 shares, Andy Pasternak bought 45,000 shares, and Stacey Jennifer Evans also picked up 45,000 shares. These transactions were all executed on the same day without a reported purchase price or planned trade code.

About Context Therapeutics Inc.

Context Therapeutics is a Philadelphia-based biopharmaceutical firm focused on developing treatments for solid tumors. Its pipeline features CTIM-76, a bispecific antibody designed to target and redirect immune cells toward malignant cells expressing the Claudin 6 protein. The company works closely with partners like Integral Molecular to advance its oncology pipeline.

What to Watch Next for CNTX

Investors will keep an eye on upcoming regulatory updates and clinical trial progress for CTIM-76 to gauge the company's path forward. Further insider filings and future quarterly reports will provide more insight into how management and affiliates view the firm's long-term prospects.